*IMPORTANT NOTE* - Because of the nature of the Emergency Use Authorizations (EUA) these can only be performed in the US, consistent with the terms of the US EUA Fact Sheet, and in countries where use of molnupiravir is authorized under the terms of the US EUA Fact Sheet. Proposals in this category must be proof-of-concept only; we will not consider any placebo controlled or blinded studies or studies anticipated to enroll large numbers of subjects. We are not considering any pre- or post- exposure prophylaxis studies in non-SARS-COV-2 infections.
Please complete the corresponding clinical PROTOCOL and BUDGET (NON-INTERVENTIONAL OR INTERVENTIONAL) templates via the Company's on-line study management system (in US) or your MSD country representative (outside US). The submissions will be collectively reviewed and selected by the MISP Committee.
Critical Activities and Timelines:
Activity | Review Cycle 3 |
---|---|
SUBMISSION DEADLINES
|
October 31, 2022 |
Support Material
iEnvision-Visiontracker Site
Applicant Guide
Instructions: Correlative Data Entry
General Medicine | Infectious Diseases | Vaccines
Non-Clinical Protocol Template
Non-Clinical Budget Template
---------------------------------------------------
Clinical Protocol Template---------------------------------------------------
Material Transfer Protocol Template (Compound Only, No Funding)Oncology MISP
---------------------------------------------------
Clinical Proposal Template---------------------------------------------------
Pembrolizumab Protocol Template (restricted)---------------------------------------------------
Clinical Interventional Budget TemplateOncology Translational Studies Program
OTSP Summary Template
MISP Contacts
Information